Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Receive an affordable massage at home and on-demand by easily booking straight from an app. Since the start of year, Urban Massage has delivered more than 114,000 massages and received a 4.85/5 or above rating for the level of treatment provided to their customers. The company has successfully launched in Birmingham, Manchester and Paris with an Annualised Run Rate (ARR) of 3,300% from June 2014 and in June 2018, an ARR of £10.4m.
days to go:
Expired
investment:
£3,491,730
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go:
Expired
investment:
£5,877,517
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Amino focuses on targeted nutrition using amino acids to improve human health, emphasizing the untapped potential beyond sports and bodybuilding. Currently offering pre- and intra-workout amino acid drinks, the company aims to expand its product line to cater to a broader consumer base, believing the market lacks variety in ready-to-mix powdered blends. Backed by scientific research and a commitment to taste and accessibility, Amino aspires to emerge as the leading global brand in amino acid products.
days to go:
Expired
investment:
£193,219
Milbotix, a healthtech start-up, supported by the Alzheimer's Society and the UK Dementia Research Institute, is driven by its innovative product SmartSocks™. This wearable technology aims to assist individuals with dementia facing communication challenges and their caregivers. Globally, the number of people with dementia is increasing significantly, reaching 78 million by 2030 and 139 million by 2050. Half of those diagnosed with dementia encounter challenging behavioral symptoms due to distress. Early distress management not only enhances well-being but also helps prevent escalating behavioral issues. SmartSocks™ utilize sensors and artificial intelligence to notify dementia caregivers about early signs of pain and anxiety in their patients.
days to go:
Expired
investment:
£220,780
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.
days to go:
Expired
investment:
£891,790
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go:
Expired
investment:
£167,619
